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Objectives: To determine trends in clinical practice for individuals with DSD requiring gonadectomy.
Design: Retrospective cohort study.
Methods: Information regarding age at gonadectomy according to diagnosis; reported sex; time of presentation to 
specialist centre; and location of centre from cases reported to the International DSD Registry and who were over 16 
years old in January 2019.
Results: Data regarding gonadectomy were available in 668 (88%) individuals from 44 centres. Of these, 248 
(37%) (median age (range) 24 (17, 75) years) were male and 420 (63%) (median age (range) 26 (16, 86) years) were 
female. Gonadectomy was reported from 36 centres in 351/668 cases (53%). Females were more likely to undergo 
gonadectomy (n = 311, P < 0.0001). The indication for gonadectomy was reported in 268 (76%). The most common 
indication was mitigation of tumour risk in 172 (64%). Variations in the practice of gonadectomy were observed; of 
the 351 cases from 36 centres, 17 (5%) at 9 centres had undergone gonadectomy before their first presentation to the 
specialist centre. Median age at gonadectomy of cases from high-income countries and low-/middle-income countries 
(LMIC) was 13.0 years (0.1, 68) years and 16.5 years (1, 28), respectively (P < 0.0001) with the likelihood of long-term 
retention of gonads being higher in LMIC countries.
Conclusions: The likelihood of gonadectomy depends on the underlying diagnosis, sex of rearing and the geographical 
setting. Clinical benchmarks, which can be studied across all forms of DSD will allow a better understanding of the 
variation in the practice of gonadectomy.
Introduction
Differences or disorders of sex development (DSD) are a 
heterogeneous group of conditions, that can be associated 
with gonadal dysfunction and germ cell cancers (1). The 
estimated prevalence of germ cell tumours ranges from 
0.8 to 40% depending on age and underlying diagnosis 
(2, 3). To mitigate this tumour risk, as well as for avoiding 
the possibility of hormone production that is discordant 
to the gender, children and adolescents with DSD have 
often undergone gonadectomy (4, 5). However, when 
counselling patients as well as their parents in case 
of a child with DSD, a careful balance must be sought, 
between mitigating this risk, preserving any residual 
gonadal function and encouraging patient participation 
in decisions regarding gonadectomy (4). Whilst single 
centre and single condition reports of the experience of 
gonadectomy in cases of DSD do exist (5, 6, 7, 8), there 
is little information on variations in care as well as any 
emerging trends in the timing of gonadectomy. More 
recently, there has been an increasing emphasis on 
delaying gonadectomy in a range of conditions associated 
with DSD (9) especially when there is a possibility that 
informed consent cannot be obtained from the young 
patient (10). The primary aim of the current study was 
to use the I-DSD Registry to investigate recent trends 
in gonadectomy internationally for a wider range of 
conditions associated with DSD. In addition, the use of 
objective outcomes including age at gonadectomy, sex of 
rearing and time of presentation was explored.
Methods
The I-DSD Registry was interrogated for information 
regarding year of birth, age at presentation to a specialist 
centre, the diagnosis, karyotype and sex of rearing of all 
cases who were over the age of 16.0 years in January 2019 
and who had a disorder of androgen action, androgen 
synthesis or gonadal development; Leydig cell hypoplasia; 
persistent Müllerian duct syndrome or a non-specific 
DSD. The I-DSD registry is an international database of 
pseudo-anonymised information on patients with DSD 
and is approved by the National Research Ethics Service 
in the United Kingdom (IRAS 269776 and Research Ethics 
Committee reference 19/WS/0131) as a research database 
of information that is collected as part of routine clinical 
care at specialist DSD centres (11) and further details are 
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available at www.i-dsd.org. Throughout the manuscript, 
the terms male/female refer to reported sex at the time of 
the study, as reported by clinicians on the I-DSD Registry. 
The cut-off of 16 years was chosen to enable a reasonable 
time-lapse between diagnosis and gonadectomy to better 
understand when gonadectomies were performed. For 
eligible cases, the reporting clinicians were approached for 
information on gonadectomy, and in those cases that had 
undergone gonadectomy, additional data were collected 
on age at gonadectomy, indication for gonadectomy and 
histology result, if available.
Data management and statistical analysis
The data received from each centre were collated and stored 
on Microsoft Excel version 16.4 and accessed only by ALH 
and SFA, as the principal investigators who planned the 
original data analysis. Where incomplete data were available, 
for example lack of information regarding indication or 
histology, this was indicated. Data were quality checked to 
ensure no duplicate patients were entered, for example in 
the case of a patient moving care from one I-DSD centre to 
another. To assess temporal differences, comparisons were 
performed between individuals born before 1999 and after 
1999, to approximate with the increasing awareness of the 
John vs Joan case (12, 13). For assessment of geographical 
differences in practice, participating centres were categorised 
as those from a low- or middle-income country (LMIC) or 
from a high-income country (HIC) as defined by the 2019 
World Bank classification (14). Continuous variables were 
described as median and ranges and normality was assessed 
via the Shapiro–Wilk test. Inter-group comparison for these 
variables was performed by the Mann–Whitney U test or 
one way ANOVA as appropriate. The Fisher exact test was 
performed to compare proportions in different groups. 
Linear regression was performed to assess associations 
between trends of gonadectomy and odds ratios calculated 
for likelihood of gonadectomy. The level of P < 0.05 was 
considered to be statistically significant and all analyses 
were performed using Graphpad Prism 8 (San Diego, CA, 
2018).
Results
Description of cases in the registry
At the time of the study, there were 3618 records on the 
I-DSD Registry. Of these, 757 (21%) met the study inclusion 
criteria and in 668 (88%) of these cases, information on 
gonadectomy status was available (Supplementary Fig. 1, 
see section on supplementary materials given at the end of 
this article). These cases were registered from 44 different 
centres in 21 different countries, over five continents with 
a median number of cases per centre of 5 (range 1, 215). 
Of the 668 cases, 248 (37%) with a median age of 24 years 
(17, 75) were registered as male and 420 (63%) with a 
median age of 26 years (17, 86) were registered as female. 
The karyotype was 46,XY in 520 (78%), 45,X/46,XY in 44 
(7%), 46,XX in 35 (5%), 47,XXY in 34 (5%), 46,XX/46,XY 
in 8 (1%) and other in 27 (4%). Of those with 46,XX 
karyotypes, 12 (34%) had a diagnosis of ovotesticular DSD, 
8 (23%) had testicular DSD, 5 (14%) had partial gonadal 
dysgenesis, 5 (14%) had complete gonadal dysgenesis, 2 
(6%) had gonadal regression and 3 (9%) had non-specific 
DSD (NS-DSD). The most common conditions that 
were reported included complete androgen insensitivity 
syndrome (CAIS) (n = 161, 24%) and partial gonadal 
dysgenesis (n = 94, 14%).
Description of cases of gonadectomy
Of the 668 cases, gonadectomy was reported in 351 
(53%) (Table 1) in 36 centres from 18 countries, and of 
these, 15 (42%) centres were located in 9 (50%) countries 
categorised as LMIC. In those cases that had gonadectomy, 
the karyotype was 46,XY in 302 (86%); 46,XX in 7 (2%); 
45,X/46,XY in 28 (8%); 46,XX/46,XY in 4 (1%); 47,XXY in 
1 (0.5%) and other in 9 (2.5%). Of the 420 females in the 
cohort, 311 (74%) had a history of bilateral gonadectomy 
compared to 40 of the 248 males who had gonadectomy, 
and in whom 19 (48%) had bilateral gonadectomy 
(P < 0.0001). The most common diagnoses in the females 
who had gonadectomy were CAIS (n =129) and partial 
gonadal dysgenesis (n = 28) but approximately 30% of 
females with these conditions had not had gonadectomy 
and their median age at the time of the study was 25 (17, 
69) (Table 1 and Supplementary Fig. 1). In males, the 
highest rates of gonadectomy were reported in those with 
partial gonadal dysgenesis (n = 15), but even in this group, 
the majority had no history of gonadectomy (n = 34).
Of the 351 cases with gonadectomy, the primary 
indication was reported in 246 (70%) cases with mitigation 
of tumourigenesis risk in 172 (70%) and concordance 
to sex assignment in 74 (30%). Of the 172, who had 
gonadectomy for mitigation of tumourigenesis risk, 73 
(42%) had a disorder of gonadal development, 68 (40%) 
had CAIS, 14 (8%) had a disorder of androgen synthesis, 
11 (6%) had PAIS and 6 (4%) had NS-DSD. Of those who 
had gonadectomy for concordance to sex assignment, 22 
(30%) had a disorder of androgen synthesis, 20 (27%) had 
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https://eje.bioscientifica.com Table 1 The number and median age of females and males according to diagnosis. Data are presented as n (%) or as median (range).
CAIS PGD CGD NS-DSD 17β HSD 3 def PAIS 5α RD 2 def Other Whole cohort
Females
 All
  n 161 36 80 7 37 29 15 55 420
  Cases of gonadectomy 129 (80%) 28 (78%)* 62 (78)* 7 (100%)* 24(65%) 24 (83%)* 11 (73%) 26 (53%) 311 (74%)*
  Age (years) at presentation 15 (0, 32) 0.1 (0.1, 30) 14 (0.1, 21) 0.1 (0.1, 12) 7 (0.1, 38) 11 (0.1, 20) 3 (0.1, 33) 13 (0.1, 34) 13 (0, 38)
 Cases of Gonadectomy
  Age (years) at gonadectomy 16 (0.3, 68) 6 (0.1, 21) 14 (0.1, 25) 22 (18, 42)* 9 (0.5, 28) 8 (0.5, 24) 6 (2, 17) 13 (0.4, 26) 15 (0.1, 68)*
  Prior to presentation at specialist centre† 6 (38%) 0 (0%) 4 (25%) 0 (0%) 1 (5.5%) 2 (13%) 1 (5.5%) 2 (13%) 16 (94%)
 Cases with retained gonads
  n (%) 32 (20%) 8 (22%)* 18 (22%)* 0 (0%* 13 (35%) 5 (17%)* 4 (17%) 29 (47%) 109 (26%)
  Age (years) at presentation 14 (0.1, 51) 9 (0.1, 17) 13 (0.1, 20) n/a 14 (0.1, 17) 1 (0.1, 12) 24 (17, 28)* 12 (0.1, 39)* 14 (0.1, 51)
  Current age 27 (17, 86) 34 (17, 61) 28 (17, 48) n/a 28 (24, 47) 23 (18, 28) 27 (18, 37) 22 (17, 58) 27 (17, 86)
Males
 All
  n 0 58 11 33 2 50 10 84 248
  Cases of gonadectomy 0 (0%) 15 (26%) 2 (18%) 5 (15%) 0 (0%) 3 (6% 0 (0%) 15 (17%) 40 (16%)
  Age (years) at presentation n/a 0.5 (0.1, 4) 3 (2, 4) 12 (9,15) n/a 29 (3, 54) n/a 0.3 (0.1, 19) 0.3 (0.1, 53)
 Cases of Gonadectomy
  Age (years) at gonadectomy n/a 17 (0.1, 13) 5 (4, 5) 12 (3, 42) n/a 41 (5, 75) n/a 19 (4, 28) 9 (0.1, 75)
  Prior to presentation at specialist centre† n/a 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 1 (6)
 Cases with retained gonads
  n (%) 0 (0%) 43 (74%) 9 (82%) 28 (85%) 2 (100%) 47 (94%) 10 (100%) 69 (83%) 208 (84%)
  Age (years) at presentation n/a 13 (0.1, 51) 1 (0.1, 34) 0.1 (0.1, 15) 16 (13, 19) 0.3 (0.1, 20) 3 (0.1, 25) 1 (0.1, 59) 2 (0.1, 59)
  Current age n/a 32 (17, 72) 29 (24, 48) 19 (17, 47) 26 (23, 28) 24 (18, 44) 29 (17, 57) 25 (17, 75) 27 (17, 75)
*P < 0.05 compared to males. Analysis via one way ANOVA or Chi-square as appropriate; †The number of cases of gonadectomy prior to presentation to the specialist centre was calculated according 
to date of presentation and date of first presentation at the specialist centre.
17β HSD 3 def, 17β hydroxysteroid deficiency type III; 5α RD 2 def, 5α reductase deficiency type 2; CAIS, Complete Androgen Insensitivity Syndrome; CGD, Complete Gonadal Dysgenesis; NS-DSD, 





































CAIS, 18 (24%) had a disorder of gonadal development, 
9 (12%) had PAIS and 5 (7%) had NS-DSD. There was 
no correlation between year of birth and indication for 
gonadectomy (P =0.6).
Age at gonadectomy
Of the 351 cases who had gonadectomy, data on both, age 
at gonadectomy and age at reported time of presentation, 
was available in 296 (79%) (Table 1). As expected, age at 
gonadectomy was associated with the age at presentation 
(P < 0.0001) with the age at gonadectomy increasing 
with an increasing age at presentation, irrespective of the 
underlying diagnosis (Fig. 1A). However, the underlying 
diagnosis when coupled with the sex of rearing, did 
influence the interval between age at presentation and 
age at gonadectomy such that females with CAIS were 
more likely to be older at gonadectomy compared 
to age at presentation (Fig. 1A). Overall, females had 
gonadectomy later, at a median age of 15 years (0.1, 68), 
compared to males who had gonadectomy at a median 
age of 9 years (0.1, 54) (P = 0.047) (Table 1). There were 
no statistically significant differences between diagnoses. 
There were no statistically significant trends for a change 
in the age at gonadectomy according to indication for 
gonadectomy (Fig. 1B) or over time (Fig. 1C). Of those 
who were diagnosed under the age of 10 yrs, there 
was no difference in age at gonadectomy in those who 
were born prior to 1990 compared to those who were 
born between 1990 and 1999 (median age 5 years vs 
6 years, P = 0.2).
Gonadectomy prior to presentation to 
specialist centre
Of the 351 cases of gonadectomy where information 
on age at gonadectomy was available, 17 (5%) (16 
females and 1 male), had gonadectomy performed 
before presentation to the specialist centre (Fig. 2A). 
Of these 17 patients, 6 (38%) had CAIS; 4 (24%) had 
CGD; 3 (18%) had PAIS and there was one case each of 
17β-dehydrogenase type 3 deficiency, 5-α-reductase type 
2 deficiency, Leydig cell hypoplasia and non-specific XY 
DSD. The median reported age at presentation for these 
individuals was 16 years (3, 38) with a median period of 
4 years (0.2, 23) from gonadectomy to presentation to 
specialist centre. Only 6 of these 17 (35%) cases were born 
after 1990 but linear regression analysis did not identify 
Figure 1
Age at gonadectomy according to diagnosis, year of birth and 
age at presentation to specialist centre. (A) Age at 
gonadectomy according to diagnosis and age at presentation 
to specialist centre. There was no difference in age at 
gonadectomy according to diagnosis. Analysis via linear 
regression. The lines represent the median and 95% CI. PAIS, 
Partial Androgen Insensitivity Syndrome; CAIS, Complete 
Androgen Insensitivity Syndrome; DGD, disorder of gonadal 
development; DAS, disorder of androgen synthesis; NS/other, 
non-specific DSD or other disorder type. (B) Age at 
gonadectomy according to indication for gonadectomy and 
age at presentation to specialist centre. There was no 
difference in age at gonadectomy according to diagnosis. The 
lines represent the median and 95% CI. (C) Age at 
gonadectomy according to year of birth and age at 
presentation. Age at presentation did affect age at 
gonadectomy. The lines represent the median and 95% CI.
































a statistically significant temporal trend for a change 
in the number of individuals with gonadectomy prior 
to presentation according to the year of birth (P = 0.3) 
(Fig. 2B). The 17 cases that had gonadectomy prior to 
reported presentation to the specialist centre were from 
9/36 (34%) centres (Fig. 2C). The proportion of registered 
patients from each centre who underwent gonadectomy 
prior to presentation to the specialist centre varied from 
0 to 100% (Fig. 2D). There was a wide range of variability 
in the number of gonadectomies performed per centre, 
with the median being 1 (1, 126) although there was no 
statistically significant difference in the number of cases 
with gonadectomy before specialist presentation in those 
centres that reported more cases of gonadectomy (Fig. 2E).
Geographical differences
Of the 327 cases from LMIC centres, 95 (29%) had 
undergone gonadectomy whilst of the 341 cases from 
HIC, 256 (75%) had undergone gonadectomy (P < 0.0001). 
The median age at diagnosis of cases from HIC and LMIC 
was 6 years (0.1, 53) and 14 years (0.1, 38), respectively 
(P = 0.015) and the median age at gonadectomy of 
cases from HIC and LMIC was 13 years (0.1, 68) years 
and 16.5 years (1, 28), respectively (P < 0.0001). Of 
the 95 cases in LMIC centres, a disorder of gonadal 
development was the commonest condition in 43 cases 
(45%). In HIC, the commonest group of conditions was 
a disorder of androgen action in 131 cases (51%) (Table 
2). Compared to HIC centres, the likelihood of retaining 
gonads was greater in LMIC centres for CAIS (OR (95% 
CI): 18.5 (7.3–47.5), P < 0.0001), CGD (OR (95% CI): 31.1 
(8.3–91.8, P < 0.0001), 17β HSD 3 deficiency (OR (95% 
CI): 28 (3.2, 31.8), P < 0.01) and PAIS (OR (95% CI): 4.1 
(1.5–11.9, P < 0.01). There were no significant differences 
in age at presentation or age at gonadectomy according 
to underlying diagnosis in LMIC centres vs HC centres. 
There was no statistically significant difference in the 
number of cases with gonadectomy prior to presentation 
to the specialist centre in those from LMIC centres vs 
HIC centres. Of the 17 cases with gonadectomy prior to 
specialist presentation, 5 (29%) were from 4 LMIC centres 
and 12 from 5 HIC centres.
Histology
Of the 351 cases of gonadectomy, histology data were 
available in 266 (76%), and of these, tumours were detected 
in 11 (4%) with a median age of 14 years (5, 74); 6 (55% of 
those with tumours; 8% of CGD cases with gonadectomy) 
had complete gonadal dysgenesis; 2 (18% of those with 
tumours; 6% of PGD cases with gonadectomy) had 
partial gonadal dysgenesis; 1 (9% of those with tumours; 
1% of CAIS cases with gonadectomy) had CAIS; 1 (9% 
of those with tumours; 8% of ovotesticular DSD cases 
with gonadectomy) had ovotesticular DSD and 1 (9% of 
those with tumours; 100% of Persistent Müllerian Duct 
Syndrome (PMDS) cases with gonadectomy) had PMDS. 
The tumours were germ cell neoplasia in situ in 3 (27%) (1 
case each of CGD, partial gonadal dysgenesis and PMDS); 
gonadal germ cell tumours in 6 (55%) (5 cases of CGD and 
Figure 2
Proportion of individuals undergoing gonadectomy prior to 
presentation at the specialist centre according to sex, 
underlying diagnosis, year of birth, age at presentation and 
location of specialist centre. (A) Proportion of individuals 
undergoing gonadectomy prior to presentation at the 
specialist centre for females (left) and males (right) according 
to underlying diagnosis. (B) Proportion of individuals 
undergoing gonadectomy prior to presentation at the 
specialist centre according to age at presentation. (C) 
Proportion of individuals undergoing gonadectomy prior to 
presentation at the specialist centre, with LMIC and HIC 
countries highlighted. (D) The number of registered 
participants undergoing gonadectomy compared to the 
number of participants registered from that specialist centre. 
The symbols with the white circle and black outline represent 
LMIC and HIC centres. CAIS, Complete Androgen Insensitivity 
Syndrome; DGD, disorder of gonadal development; DAS, 
disorder of androgen synthesis; HIC, high-income country; 
LMIC, low- to middle-income country; NS/other, non-specific 
DSD or other disorder type; PAIS, Partial Androgen Insensitivity 
Syndrome.
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Table 2 The number and median age of individuals from LMIC and HIC according to diagnosis. Data are presented as n (%) or as median (range).
CAIS PGD CGD NS-DSD 17β HSD 3 def PAIS 5α RD 2 def Other Whole cohort
LMIC
 All
  n 42 38 33 13 22 34 19 126 327
  Cases of gonadectomy 18 (43%) 16 (42%) 10 (30%) 3 (23% 8 (36%) 6 (18%) 6 (30%) 28 (22%) 95 (29)
  Age (years) at presentation 15 (0.1, 25) 4 (0.1, 16) 14 (0.3, 16) 14 (11, 15) 16 (3, 38) 12 (0.1, 17) 14 (0.1, 33) 8 (0.1, 23) 14 (0.1, 38)
 Cases of Gonadectomy
  Age (years) at gonadectomy 17 (13, 27) 14 (9, 21) 17 (10, 19) 15 (14, 16) 17 (7, 28) 14 (7, 18) 13 (8, 17) 16 (1, 28) 16 (1, 28)
  Prior to presentation at specialist centre† 1 (6%) 0 (0%) 1 (3%) 0 (0%) 1 (13%) 1 (17%) 0 (0%) 1 (4%) 5 (3%)
 Cases with retained gonads
  n (%) 24 (57%) 22 (58%) 23 (70%) 10 (77%) 14 (64%) 28 (82%) 13 (70%) 98 (78%) 232 (71%)
  Age (years) at presentation 25 (18, 49) 4 (0.1, 27) 16 (2, 20) 12 (0.1, 12) 19 (3, 19) 4 (0.1, 20) 11 (0.1, 28) 12 (0.1, 25) 25 (0.1, 49)
  Current age 15 (5, 51) 17 (17, 34) 24 (17, 36) 24 (16, 40) 30 (18, 35) 23 (16, 34) 22 (16, 42) 22 (16, 37) 15 (16, 51)
HIC
 All
  n 119 56 58 27 17 45 6 13 341
  Cases of gonadectomy 111 (93%) 27 (48%) 54 (93%) 9 (33%) 16 (94%) 21 (47%) 5 (100%) 13 (100% 256 (75%)
  Age (years) at presentation 14 (0, 32) 0.1 (0.1, 30) 10 (0.1, 21) 9 (0.1, 14) 3 (0.1, 32) 11 (0.1, 54) 0.1 (0.1, 3) 1 (0.1, 17) 6 (0.1, 53)
 Cases of Gonadectomy
  Age (years) at gonadectomy 16 (0.3, 68) 1 (0.1, 18) 12 (0.1, 25) 14 (3, 42) 6 (0.5, 19) 13 (0.5, 75) 3.5 (2, 7) 13 (0.5, 34) 13 (0.1, 68)
  Prior to presentation at specialist centre† 5 (5%) 0 (0%) 3 (6%) 0 (0% 0 (0%) 2 (10%) 1 (20%) 1 (8%) 12 (5%)
 Cases with retained gonads
  n (%) 8 (7%) 29 (52%) 4 (7%) 18 (67%) 1 (6%) 24 (53%) 1 (0%) 0 (0%) 85 (25%)
  Age (years) at presentation 15 (1, 51) 0.1 (0.1, 51) 0.1 (0.1, 34) 11 (0.1, 15) 9 (0.1, 12) 3 (0.1, 13) 2 (0.1, 28) 11 (1, 59) 27 (0.1, 59)
  Current age 32 (16, 86) 28 (16, 72) 27 (16, 48) 20 (17, 47) 29 (16, 47) 26 (16, 44) 24 (16, 57) 24 (16, 75) 11 (16, 86)
17β HSD 3 def, 17β hydroxysteroid deficiency type III; 5α RD 2 def, 5α reductase deficiency type 2;CAIS, Complete Androgen Insensitivity Syndrome; CGD, Complete Gonadal Dysgenesis; HIC, 





































1 case of partial gonadal dysgenesis) and dysgerminoma 
in 2 (18%) (1 case each of ovotesticular DSD and CGD). 
Data on histology were available for 9 out of 17 cases 
(53%) who had gonadectomy prior to presentation to the 
specialist centre and none of these had any histological 
evidence of tumourigenesis.
Discussion
This study demonstrates differences that exist in the 
practice of gonadectomy and that are dependent on 
the underlying diagnosis, the sex of rearing and the age 
at presentation. Clear patterns have previously been 
reported for conditions such as CAIS, where high rates 
of affected women have undergone gonadectomy (15) 
and these were reinforced in the current study. However, 
previous reports of gonadectomy in other forms of DSD, 
for example 17-β dehydrogenase type 3 deficiency, 5-α 
reductase type 2 deficiency or non-specific XY DSD are 
rare. In some of these conditions that are associated with 
a disorder of androgen synthesis, the indication for early 
gonadectomy was the avoidance of pubertal virilisation 
in an XY girl. Given that more children with XY DSD 
are being raised as boys (12), there is a greater prospect 
of preserving gonadal function and fertility (16, 17) and 
there is a greater emphasis on the patient’s own views 
on gonadectomy (4, 18, 19), there has been an increased 
emphasis on retaining gonads until the age when patients 
with DSD can decide for themselves (20).
Mitigation of tumour risk was the commonest reported 
indication for performing gonadectomy and therefore as 
expected, in the current study, the number of cases that 
actually had any evidence of tumour development was 
very small. It is also noteworthy, that the conditions that 
were associated with a tumour included a case of PMDS 
and ovotesticular DSD, two conditions where the risk of 
gonadal tumourigenesis has generally been considered 
to be low (21, 22). Thus, the study emphasizes the need 
for ongoing monitoring of these outcomes in those 
conditions that are traditionally thought to be low risk. 
The study also demonstrated that a substantial proportion 
of cases continued to retain gonads into adulthood, even 
in conditions such as gonadal dysgenesis, where the risk 
of germ cell tumours is particularly high (18, 23).
With the shifts in societal attitudes, it would be useful 
to prospectively monitor the age at presentation and the 
age at gonadectomy. The current study showed that, in 
about 1 in 20 cases, the age at gonadectomy was prior to 
the age at presentation to a specialist DSD centre. There 
may be many reasons why this was the case. It is assumed 
that all of these individuals had specialists involved in their 
care outwith the DSD reference centre but a prospective 
study would allow this to be monitored and it is hoped 
that with improved awareness of DSD conditions, fewer 
affected individuals are being referred late to specialists 
in this field. It was also noteworthy that there were 
variations in practice between LMIC and HIC centres with 
the proportion of cases that had a gonadectomy being 
lower in LMIC countries. The older age at gonadectomy 
at the LMIC centres may be secondary to an older age at 
presentation in these cases but the lower proportion of 
cases undergoing gonadectomy may be due to difficulties 
in access to specialist diagnostic or surgical services 
(19, 24) or due to differences in cultural and societal 
attitudes to gonadectomy (25). These aspects as well as 
the surveillance measures that are used for monitoring 
retained gonads will need to be explored in future studies.
Over the last few decades, it has become increasingly 
clear that the risk of tumour development in conditions 
associated with DSD is dependent on the underlying 
condition. It is likely that the decision to perform 
gonadectomy is influenced by this knowledge as well 
as other variables, as above. Thus, the management of 
gonads requires a detailed understanding of all these 
factors which can only be provided by a specialist team 
that can call on this multidisciplinary expertise (4). 
The I-DSD Registry represents a valuable resource that 
can facilitate the study of clinical practice in this large 
heterogenous group of rare conditions. Studies using this 
resource have previously revealed the global shift in the 
practice of sex assignment (12) and more recent studies 
have shown how practices vary in the management of 
the testes in people with AIS (15). The current study has 
taken this further by showing how these differences can 
be described objectively to study temporal and regional 
variations for a wide range of conditions associated with 
DSD. We would recommend that all cases of gonadectomy 
should be recorded in a registry such as the I-DSD Registry 
for the purpose of long-term audit and surveillance.
In the process of performing this study, we believe 
that we have identified simple, yet effective, clinical 
benchmarks, that is, the number of individuals 
undergoing gonadectomy prior to review at a specialist 
centre or the age of presentation compared to the age 
at gonadectomy. Benchmarking represents a continual 
and collaborative effort at measuring and comparing 
the results of key processes that are directly relevant to 
patients with an eventual aim of improving clinical 
outcomes (26). Gaps in the professional development of 
































service providers have been reported before (27, 28) and 
it is possible that targeting simple observations such as 
these leads to greater local awareness of the pros and cons 
of early gonadectomy. It is likely that there is an optimal 
balance to be achieved between timely gonadectomy and 
a well-informed patient or parent and further exploration 
of these measures may allow the identification of this 
optimal range. Identification of benchmarks that target 
specific points in the care pathway of the patient with 
gonadectomy may lead to improvement of this pathway 
but this will require further exploration. For instance, most 
specialist centres that participate in the I-DSD Registry act 
as regional centres of referral and it is possible that greater 
outreach links and education programmes between such 
specialist centres and the referral catchment area may 
lead to greater informed decision making. Knowledge and 
awareness can be promoted locally through participating 
in joint clinics or local educational activities within the 
referral network and the availability of such opportunities 
has been previously reported by DSD centres to be 
variable (27).
There are, however, some limitations to using the 
number of individuals undergoing gonadectomy prior to 
review at a specialist centre as a clinical benchmark. The 
definition of a specialist centres was based on the centre 
participating in the I-DSD Registry and it is of course 
possible that the centre prior to presentation to the I-DSD 
centre was also an expert centre. Future work should 
examine the complete pathway of care of the patient 
who undergoes gonadectomy more comprehensively. 
With only 1 in 20 individuals undergoing gonadectomy 
prior to presentation to a specialist centre, the need for 
further research and prospective monitoring of timing 
of gonadectomy is important to confirm whether the 
findings in the current study were simply a chance 
finding.
It is possible that this study may suffer from some 
selection bias, as not every patient at a centre may have 
been included in the Registry. On the other hand, the 
structured manner of real-world data collection within 
the Registry, the size of the cohort and its potential 
to represent global practice were clear strengths. In 
addition, as with any large database, errors may occur 
with data entry; however, in all data that were analysed 
were checked with the centres at the time of the study 
to ensure it matched with the source data. Although, the 
investigators did not have recourse to source data, the data 
that have been collected have previously been reported to 
have a high degree of reliability (29). Comparison of the 
case mix that exists in the I-DSD Registry (30) to the range 
of cases that may exist in a specialist service (31) also 
shows remarkable similarities. For a greater understanding 
of the practice of gonadectomy, it would be helpful to 
have further information on gonadal position, post-
operative complications, patient and parental decisional 
regret, complications of gonads that are left in situ, 
geographical and temporal differences in social attitudes, 
local health care resources and, very importantly, the 
extent of information provision to patients and parents. 
These aspects were beyond the scope of the Registry but 
deserve further study. The current study was aimed at 
studying individuals older than 16 years at the time of 
data collection. Data from younger individuals would also 
be of interest, particularly in conditions for which the risk 
of germ cell tumour is high early in life. A prospective 
study, condition-specific study would also allow more 
valuable information on condition-specific trends which 
has not been possible in the current study due to the small 
numbers.
To conclude, this global collaborative effort has clearly 
demonstrated that although the timing of gonadectomy 
depends on the condition and the age of the patient, 
there is considerable variation between centres. Objective 
parameters that have been identified as part of this 
work may serve as benchmarks of practice that can be 
prospectively monitored.
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